Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087074 · ClinicalTrials.gov registry record · Phase 2
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
A Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Gastrointestinal Stromal Tumor, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT00087074: Completed Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Gastrointestinal Stromal Tumor, sponsored by National Cancer Institute (NCI).
NCT00087074 is a Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Gastrointestinal Stromal Tumor that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 55 participants, below the 84-participant average among 11 other Recurrent Adult Soft Tissue Sarcoma trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00087074, a Phase 2 study of Recurrent Adult Soft Tissue Sarcoma and Gastrointestinal Stromal Tumor, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial is studying how well CCI-779 works in treating patients with soft tissue sarcoma or gastrointestinal stromal tumor. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG temsirolimus
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2004-06 |
| Phase | Phase 2 |
What the finished NCT00087074 record still lists
NCT00087074 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 84-participant average among 11 other Recurrent Adult Soft Tissue Sarcoma trials with a reported enrollment target (35% lower).
The record links to 6 conditions, with Recurrent Adult Soft Tissue Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00087074 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00087074 about?
NCT00087074 is a clinical study titled "CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor". This phase II trial is studying how well CCI-779 works in treating patients with soft tissue sarcoma or gastrointestinal stromal tumor. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die.
What is the current status of trial NCT00087074?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2004-06.
What conditions does trial NCT00087074 study?
This clinical trial studies the following conditions: Recurrent Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Stage IV Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma.
What interventions are being tested in trial NCT00087074?
The interventions under investigation include: laboratory biomarker analysis (OTHER), temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00087074?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00087074 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adult Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00087074's enrollment target sits among peer trials
55 8th of 11 higher than 4 of 11 other Recurrent Adult Soft Tissue Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Adult Soft Tissue Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
COMPLETED · Phase 2
-
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
COMPLETED · Phase 2
-
Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
COMPLETED · Phase 2
-
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma
COMPLETED · Phase 2
-
A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas
COMPLETED · Phase 2
-
Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia